Accolade’s (ACCD) “Hold” Rating Reiterated at Stifel Nicolaus

Stifel Nicolaus reaffirmed their hold rating on shares of Accolade (NASDAQ:ACCD) in a research note published on Thursday morning,Benzinga reports. Stifel Nicolaus currently has a $7.03 price objective on the stock, down from their previous price objective of $8.00.

ACCD has been the topic of a number of other research reports. Needham & Company LLC reiterated a “hold” rating on shares of Accolade in a research report on Wednesday. Barclays decreased their target price on Accolade from $5.50 to $5.00 and set an “equal weight” rating on the stock in a research report on Wednesday, October 9th. Morgan Stanley decreased their price objective on Accolade from $6.00 to $5.00 and set an “equal weight” rating on the stock in a report on Tuesday, December 17th. Canaccord Genuity Group reissued a “hold” rating on shares of Accolade in a research report on Wednesday. Finally, Leerink Partners reissued a “market perform” rating on shares of Accolade in a research report on Wednesday. Ten equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $7.55.

Accolade Price Performance

Shares of NASDAQ ACCD opened at $6.83 on Thursday. The stock has a market capitalization of $550.07 million, a price-to-earnings ratio of -6.63 and a beta of 2.08. Accolade has a 12 month low of $3.08 and a 12 month high of $15.21. The firm’s 50 day simple moving average is $3.73 and its 200-day simple moving average is $3.82. The company has a debt-to-equity ratio of 0.49, a current ratio of 2.72 and a quick ratio of 2.72.

Accolade (NASDAQ:ACCD) last issued its quarterly earnings data on Friday, January 10th. The company reported ($0.30) EPS for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.01. Accolade had a negative net margin of 18.16% and a negative return on equity of 18.43%. Analysts expect that Accolade will post -0.92 EPS for the current year.

Insiders Place Their Bets

In other news, CEO Rajeev Singh sold 13,357 shares of the stock in a transaction that occurred on Tuesday, December 3rd. The stock was sold at an average price of $3.60, for a total value of $48,085.20. Following the completion of the sale, the chief executive officer now directly owns 814,316 shares of the company’s stock, valued at approximately $2,931,537.60. This represents a 1.61 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders have sold 40,881 shares of company stock worth $144,987 over the last three months. Company insiders own 8.20% of the company’s stock.

Institutional Investors Weigh In On Accolade

Several large investors have recently modified their holdings of ACCD. Mission Creek Capital Partners Inc. purchased a new stake in shares of Accolade during the third quarter worth approximately $38,000. IQ EQ FUND MANAGEMENT IRELAND Ltd purchased a new position in Accolade in the third quarter worth $46,000. Wolverine Trading LLC purchased a new position in Accolade in the third quarter worth $51,000. Point72 Asia Singapore Pte. Ltd. raised its position in Accolade by 1,144.1% in the third quarter. Point72 Asia Singapore Pte. Ltd. now owns 20,913 shares of the company’s stock worth $81,000 after acquiring an additional 19,232 shares in the last quarter. Finally, Intech Investment Management LLC purchased a new position in Accolade in the third quarter worth $96,000. Hedge funds and other institutional investors own 84.99% of the company’s stock.

About Accolade

Accolade, Inc, together with its subsidiaries, engages in the development and provision of personalized and technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based intelligent technology and multimodal support from a team of advocates and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, women’s health specialists, case management specialists, expert medical opinion providers, and primary care physicians.